Laurus Labs (BOM:540222) ROCE %: 22.81% (As of Mar. 2026)


BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,493.60
GF Value ₹700.37
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Laurus Labs ROCE %?

Laurus Labs BOM:540222 -1.59% 66 ROCE % is 22.81% as of Mar. 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹700.37 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Laurus Labs's annualized ROCE % for the quarter that ended in Mar. 2026 was 22.81%.

Laurus Labs  (BOM:540222) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Laurus Labs ROCE % Related Terms

Laurus Labs ROCE % Historical Data

* Premium members only.

The historical data trend for Laurus Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs ROCE % Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.59 25.89 7.77 12.48 21.20

Laurus Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.80 19.03 19.85 23.42 22.81
BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs ROCE % Calculation

Laurus Labs's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=13429.3/( ( (93355.7 - 35397.2) + (105111.9 - 36354.3) )/ 2 )
=13429.3/( (57958.5+68757.6)/ 2 )
=13429.3/63358.05
=21.20 %

Laurus Labs's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=15685.2/( ( (0 - 0) + (105111.9 - 36354.3) )/ 1 )
=15685.2/( ( 0 + 68757.6 )/ 1 )
=15685.2/68757.6
=22.81 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 22.81% mean?
Laurus Labs (BOM:540222) has a ROCE % of 22.81% as of Mar. 2026.
Is Laurus Labs' ROCE % too high?
Laurus Labs' current ROCE % is 22.81%. The Drug Manufacturers industry median ROCE % is 7.03. Laurus Labs' value of 22.81% is 224.5% above this industry median. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' ROCE % compare to ZTS and UTHR?
Laurus Labs' ROCE % of 22.81% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Laurus Labs' value of 22.81% is 224.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current ROCE % of 22.81% is 224.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current ROCE % is 22.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹700.37, compared to a current price of ₹1,493.60 — trading 113.3% above its estimated fair value. The current ROCE % is 22.81% and 224.5% above the Drug Manufacturers industry median of 7.03. Laurus Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current ROCE % is 22.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,493.60 is trading 113.3% above its estimated GF Value™ of ₹700.37. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • ROCE %: 22.81%
  • GF Value™: ₹700.37 vs. price of ₹1,493.60 (113.3% above fair value)
  • GF Score™: 66/100 with 5 warning signs
  • Industry Position: 224.5% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,493.60
Price
₹700.37
GF Value